FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for treating arthritic diseases. An agent for treating arthritic diseases comprising 50 to 2500 mg of chondroitin sodium sulphate and at least one auxiliary substance or carrier, also contains molybdenum in relative amount from 0.15 to 2 mg/kg in terms of weight of chondroitin sodium sulphate.
EFFECT: agent described above increases the bioavailability of the preparations of chondroitin sulphate in various forms by using it in combination with molybdenum, and also enables reducing the therapeutic course and reducing the negative side effects.
23 cl, 5 ex, 1 tbl, 6 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL AGENT FOR ARTHRITIC DISEASES TREATMENT | 2020 |
|
RU2739184C1 |
PHARMACEUTICAL AGENT FOR ARTHRITIC DISEASES TREATMENT | 2020 |
|
RU2739747C1 |
PHARMACEUTICAL AGENT FOR TREATING ARTHROLOGICAL DISEASES | 2023 |
|
RU2813891C1 |
LYOPHILISED PHARMACEUTICAL COMPOSITION FOR PREPARING SOLUTION FOR INJECTIONS FOR TREATING DEGENERATE-DYSTROPHIC LOCOMOTOR DISEASES AND METHOD FOR PREPARING IT | 2011 |
|
RU2458693C1 |
AGENT FOR TREATMENT OF JOINT DISEASE | 2005 |
|
RU2282437C1 |
REMEDY FOR TREATING DISEASES OF JOINTS | 2005 |
|
RU2275190C1 |
AGENT FOR TREATMENT OF ARTHROLOGIC DISEASES | 2015 |
|
RU2612014C1 |
PHARMACEUTICAL PREPARATION FOR TREATMENT OF ARTHROLOGICAL DISEASES | 2015 |
|
RU2743274C2 |
AGENT FOR TREATMENT OF JOINT DISEASES | 2005 |
|
RU2275199C1 |
METHOD FOR PREVENTING AND TREATING ARTHROPATHIES AND METHODS FOR USING SAME | 2013 |
|
RU2521973C1 |
Authors
Dates
2020-12-28—Published
2020-06-29—Filed